Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Colorcon
Medtronic
McKinsey
Boehringer Ingelheim

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC (D. Del. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC (D. Del. 2017)

Docket   Start Trial Date Filed 2017-10-11
Court District Court, D. Delaware Date Terminated 2018-09-20
Cause 35:271 Patent Infringement Assigned To Leonard Philip Stark
Jury Demand Defendant Referred To
Parties 3M COMPANY; ALVOGEN PINE BROOK LLC; ALVOGEN, INC.; NOVEN PHARMACEUTICALS, INC.
Patents 9,724,310; 9,730,900; 9,833,419
Attorneys Aaron M. Nelson; Andrew Colin Mayo; Aziz Burgy; Brett M. Garrison; Chad A. Landmon; Dominick T. Gattuso; Elizabeth Cowan Wright; Jack B. Blumenfeld; John M. Tanski; Kelly E. Farnan; Matthew J. Becker; Matthew S. Murphy; Sara M. Metzler; Stacie L. Ropka; Stephen J. Kraftschik; Theodore M. Budd
Firms Heyman Enerio Gattuso & Hirzel LLP; Morris, Nichols, Arsht & Tunnell
Link to Docket External link to docket
Small Molecule Drugs cited in Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Noven Pharmaceuticals, Inc. v. Alvogen Pine Brook LLC (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 infringement of U.S. Patent Nos. 9,730,900 (“the ’900 patent”) and 9,724,310 (“the ’310 patent”) (collectively…infringing the ’900 patent. COUNT II – INFRINGEMENT OF U.S. PATENT NO. 9,724,310 66. …collectively, “patents-in-suit”) arising under the United States Patent Laws, Title 35, United States Code § … PATENTS-IN-SUIT 35. The ’900 patent, entitled “Transdermal Estrogen…concerning the ’900 patent to the FDA in connection with NDA No. 203752, identifying it as a patent “with respect External link to document
0000-00-00 4 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,730,900 B2; 9, 724,310 B2. (lmm) (… 20 September 2018 1:17-cv-01429 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
0000-00-00 68 infringement of U.S. Patent Nos. 9,730,900 (“the ’900 patent”), 9,724,310 (“the ’310 patent”), and 9,833,419…infringing the ’900 patent. COUNT II – INFRINGEMENT OF U.S. PATENT NO. 9,724,310 72…the ’419 patent”) (collectively, “patents- in-suit”) arising under the United States Patent Laws, Title… PATENTS-IN-SUIT 35. The ’900 patent, entitled “Transdermal Estrogen…concerning the ’900 patent to the FDA in connection with NDA No. 203752, identifying it as a patent “with respect External link to document
0000-00-00 69 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,833,419 B2; . (Kraftschik, … 20 September 2018 1:17-cv-01429 835 Patent - Abbreviated New Drug Application(ANDA) External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
McKesson
Medtronic
Colorcon
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.